• EBITDA margin expansion: Metropolis aims to achieve 27–28% EBITDA margins over the next 6 to 7 quarters, driven by structural cost corrections and increased productivity across existing labs and tier-2/3 centers.
• Revenue growth drivers: Management guides for 14–15% medium-term revenue growth, comprising 9–10% patient volume growth from geographic expansion and 5–6% realization gains from its True Health and specialty segments.
• Network productivity focus: With ~220 existing labs serving 750 towns, the company plans to increase its lab-to-center ratio from 1:25 to 1:30 over the next 4–5 quarters instead of adding new laboratories.
• Specialty portfolio expansion: Specialty diagnostics accounts for roughly 40% of revenue and is growing at 17–18% year-on-year, supported by new genomics operations and oncology capabilities from the Core Diagnostics acquisition.
• Inorganic growth strategy: Backed by balance sheet cash, the company is actively pursuing bolt-on acquisitions targeting B2C assets in North and East India as well as additions to diagnostic test skill sets and technology.